Yahoo Finance Amarin First Quarter 2024 Earnings: EPS Beats Expectations
Amarin (NASDAQ:AMRN) First Quarter 2024 Results
Key Financial Results
Revenue: US$56.5m (down 34% from 1Q 2023).
Net loss: US$9.95m (loss narrowed by 40% from 1Q 2023).
US$0.024 loss per share (improved from US$0.041 loss in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Amarin EPS Beats Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 38%.
Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are down 4.5% from a week ago.
Risk Analysis
Be aware that Amarin is showing 1 warning sign in our investment analysis that you should know about...
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
